Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that regularly issues news on its operations, strategy and pipeline across generics, established brands and innovative medicines. This news page aggregates company announcements, press releases and third-party coverage related to VTRS, giving readers a single place to review the latest corporate developments.
Viatris frequently reports on regulatory milestones in its global pipeline. Recent updates include FDA approval of octreotide acetate for injectable suspension as a generic version of Sandostatin LAR Depot, FDA acceptance of a New Drug Application for a low dose estrogen weekly contraceptive patch, FDA clearance of an IND for the MR‑146 gene therapy candidate in neurotrophic keratopathy, and acceptance of a Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome. The company also announces progress in Japan and the Asia-Pacific region, such as the acquisition of Aculys Pharma and rights to pitolisant and Spydia nasal spray.
Investors can also find financial and corporate news, including quarterly results, updates to financial guidance, capital return actions like dividends and share repurchases, and information on enterprise-wide strategic reviews. Viatris’ participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and other sector events, is typically announced through press releases that are reflected in the news flow.
Additional news items may cover business development and collaborations, such as research agreements to develop engineered bacteriophage products for ophthalmic infections, as well as governance updates, board appointments and changes to corporate bylaws. For anyone tracking VTRS, this page offers a concise view of how Viatris communicates its strategy to strengthen its core portfolio, expand innovative brands and optimize its global structure.
Viatris (Nasdaq: VTRS) announced that Chief Financial Officer Theodora "Doretta" Mistras will depart for a new professional opportunity; she will remain through May 22, 2026.
Paul Campbell, Chief Accounting Officer and Corporate Controller, is named interim CFO effective May 8, 2026 while a permanent successor search is conducted. Viatris will report Q1 2026 results on May 7, 2026 and host an 8:30 a.m. ET conference call.
Viatris (Nasdaq: VTRS) announced six abstracts on its investigational low-dose estrogen combined hormonal contraceptive (MR-100A-01) will be presented at the ACOG 2026 Annual Clinical & Scientific Meeting in Washington, D.C., May 1–3, 2026. Presentations include positive Phase 3 efficacy and safety results, adhesion and pharmacokinetic data, and cycle control findings. Sessions and times for six electronic poster presentations and an educational symposium supported by Viatris are listed; Viatris will be at booth #223.
Viatris (Nasdaq: VTRS) will report first quarter 2026 financial results on Thursday, May 7, 2026. Company executives will host a live webcast at 8:30 a.m. ET the same day to discuss results.
Investors can access the live webcast at investor.viatris.com, call 844.308.3344 (domestic) or 412.317.1896 (international). A replay will be available on the company website after the call.
Viatris (Nasdaq: VTRS) will present four abstracts at the ASCRS Annual Meeting in Washington, D.C., April 10–13, 2026, covering ophthalmology data including full VEGA-3 Phase 3 results for MR-141, a Phase 1 varenicline nasal spray study in Japanese adults, and analyses of RYZUMVI and MR-142.
Presentations include oral and electronic posters; Viatris also provided an independent educational grant for a symposium on April 11, 6:00–7:30 p.m. ET, and will staff booth #233.
Viatris (Nasdaq: VTRS) announced MHLW approval of Effexor SR 37.5 mg / 75 mg for adults with generalized anxiety disorder (GAD) in Japan on March 23, 2026.
This makes Effexor the first and only approved GAD treatment in Japan; approval is supported by a Phase 3 trial (p=0.012) and long-term extension data.
Viatris (Nasdaq: VTRS) outlined a strategic plan and financial framework aimed at delivering sustained revenue and earnings growth through 2030. Key numerical targets include 5%-6% total revenues CAGR, 7%-8% adjusted EBITDA CAGR, 9%-10% adjusted EPS CAGR and > $3.0B free cash flow in 2030.
The company expects > $11 billion in cash available for deployment through 2030, identified ≈ $650 million gross cost savings, and highlighted near-term launches and pipeline assets (selatogrel, cenerimod) as potential upside drivers.
Viatris (Nasdaq: VTRS) reported Q4 2025 total revenues of $3.7B and FY2025 total revenues of $14.3B, met or exceeded 2025 guidance across key metrics, and returned over $1B to shareholders. The company completed an enterprise strategic review, expects up to $650M in net cost savings, and provided 2026 guidance while noting multiple upcoming regulatory milestones and an expected workforce reduction of up to 10%.
Key financials: Q4 adjusted EBITDA of $1.003B, Q4 adjusted EPS of $0.57, FY adjusted EBITDA of $4.16B, FY free cash flow of $1.94B, and a FY U.S. GAAP net loss of $(3.51B) reflecting a $2.9B goodwill impairment.
Viatris (Nasdaq: VTRS) announced its 2026 dividend policy of $0.48 per share and declared a quarterly dividend of $0.12 per share. The dividend is payable on March 18, 2026 to shareholders of record as of March 9, 2026.
This marks the sixth consecutive year the company has paid a dividend.
Viatris (Nasdaq: VTRS) announced FDA acceptance of the supplemental New Drug Application for MR-141 (phentolamine ophthalmic solution 0.75%) for presbyopia, with a PDUFA goal date of October 17, 2026. The sNDA is supported by positive Phase 3 VEGA-2 and VEGA-3 results that met primary and all key secondary endpoints with no treatment-related serious adverse events.
Ryzumvi (phentolamine 0.75%) is already approved in the U.S. for pharmacologically-induced mydriasis; the sNDA seeks to expand the indication to include presbyopia. VEGA-3 data will be presented at ASCRS in April and ARVO in May.
Viatris (Nasdaq: VTRS) will report fourth quarter and full year 2025 financial results on February 26, 2026 and will host a live webcast at 8:30 a.m. ET the same day. A replay will be available on the investor website.
Viatris also will host an Investor Event in New York City on March 19, 2026; additional details and pre-registration information will be provided during the February 26 investor call.